CSL Seqirus

CSL.com
CSLSeqirus.com

6 November 2026

Information regarding Q-VAX® (inactivated *Coxiella burnetii*) Vaccine (AUST R 100517) Out of Stock Notification

Dear Healthcare Professional,

CSL Seqirus wishes to advise you that Q-VAX® Vaccine will be out of stock and listed as unavailable on the Therapeutic Goods Administration (TGA) Medicines Shortage Database from early November 2026.

Q-VAX® is a biological product made from purified, inactivated *C. burnetii* bacteria. Due to the complexity of growing the bacteria under controlled conditions, batches can have biological variations that result in their delayed release.

We are working towards making more stock available as soon as possible and anticipate Q-VAX® Vaccine will be released in late December 2026 and available to customers by early January. Whilst Q-VAX® Vaccine is out of stock, CSL Seqirus will not be accepting or reviewing Q-VAX® supply requests, nor maintaining a wait list. Any requests received during the out-of stock period will not be held. We will communicate with you as soon as stock becomes available.

Although Q-VAX® Skin Test remains available, please *do not* administer Q-VAX® Skin Test to patients or run Q fever pre-screening clinics, until vaccine supply is reinstated and you have supply of vaccine at your clinic. This is due to *the requirement of reading skin tests 7 days after administering the skin test, and then vaccinating eligible individuals post-read*.

For further information on Q fever prevention, workplace risk management and occupational health requirements, Please refer to your relevant State or Territory Health Department and/or workplace safety authority resources below:

Australian Capital Territory
- ACT Health (Q fever): Q fever - ACT Government
- WorkSafe ACT: Infectious diseases - WorkSafe ACT

New South Wales
- NSW Health (Q fever): Q fever
- SafeWork NSW: Q fever | SafeWork NSW

Northern Territory
- NT Health (Health Conditions - Q fever): Q fever | NT.GOV.AU
- NT Health (Public Health & Notifiable diseases): Q fever | NT Health

Queensland
- Queensland Health (Q fever): Q fever - qld.gov.au
- WorkSafe Queensland: Q fever | WorkSafe.qld.gov.au

South Australia
- SA Health (Q fever): Q fever - including symptoms, treatment and prevention | SA Health
- SafeWork SA: Q fever | SafeWork SA

Tasmania
- Department of Health Tasmania (Q fever): Q Fever fact sheet | Tasmanian Department of Health
- WorkSafe Tasmania: Q fever

Victoria
- Victorian Department of Health (Q fever): Q fever | health.vic.gov.au
- WorkSafe Victoria: Preventing Q fever | WorkSafe Victoria

Western Australia
- WA Department of Health (Q fever): Q fever
- WorkSafe WA: Workplace zoonoses - WorkSafe WA

For other supply questions or product enquiries, please contact CSL Seqirus:
- Customer Service on 1800 008 275 or customer.service.au@seqirus.com, or
- Medical Information on 1800 642 865 or apac.medicalinformation@seqirus.com.


Please inform all relevant staff of this notice, including those at other sites/clinics to which you supply Q-Vax® vaccine or run Q fever screening and vaccination clinics.

CSL Seqirus takes its commitment to protect the public health of Australia seriously. Please know that we are doing all we can to reinstate regular supply as soon as possible. We sincerely regret any inconvenience.

Yours Sincerely,



Leonie Loyer
Director – Biosecurity, Government & In-Licensed Vaccines



Dr Jules Bayliss
Medical Director – Vaccines & Biosecurity, Australia & New Zealand

PBS Information: This product is not listed on the PBS.

Before prescribing, please review Product Information available at:
www.cslseqirus.com.au/products

Seqirus (Australia) Pty Ltd, Melbourne. ABN: 66 120 398 067. Q-VAX® is a registered trademark and CSL Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. AU-QVAX-26-0013